 |
|
Pharmacogenomics and Dermatological Therapeutics
Mark H. Lowitt, MD;
Neil H. Shear, MD, FRCPC
Arch Dermatol. 2001;137:1512-1514.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
Advances in the understanding of the structure and function of the human genome offer an opportunity to reexamine some old questions about the interplay between genetics and individual reactions to drugs. Pharmacogenetics examines questions related to individual variations in drug efficacy as well as drug toxicity. Why is it that a drug affects one individual in one way, while it may lead to a more blunted or a more dramatic therapeutic effect in another individual, or cause a serious untoward reaction in another? Why is it that the same drug can affect a person in one way on one occasion, but in a different way at another point in time? Although exogenous factors such as concomitant viral infection and multiple drug interactions may account for some variation in drug response, genetic variability in drug metabolism, drug clearance, or end-organ effect, accounts . . . [Full Text of this Article]
DRUG TOXICITY
G6PD DEFICIENCY
THE ACETYLATION POLYMORPHISM
THE CYTOCHROME P-450 SYSTEM
THIOPURINE METHYLTRANSFERASE
A PARTIALLY ANSWERED QUESTION: THE ANTICONVULSANT HYPERSENSITIVITY SYNDROME
CHALLENGES
From the Department of Dermatology, University of Maryland School of Medicine, Baltimore (Dr Lowitt); and the Divisions of Clinical Pharmacology and Dermatology, Sunnybrook & Women's College Health Sciences Center, University of Toronto Medical School, Toronto, Ontario (Dr Shear).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
